Ajaaz Hussain

Radiopharmaceutical Scientist (Clinical Trials) The Royal Marsden NHS

Ajaaz Hussain is a Radiopharmaceutical Scientist at The Royal Marsden NHS Foundation Trust, where he leads the delivery of radiopharmaceutical clinical trials, supporting the translation of innovative targeted therapies into clinical practice. He specialises in implementing complex study protocols through study set-up, radiopharmaceutical handling, pharmacokinetic sampling, quality assurance, and multidisciplinary trial coordination. His background also includes quality assurance in radiopharmacy and experience supporting Gallium-68 and Technetium-99m production. Enthusiastic about improving patient access to novel radiopharmaceuticals, Ajaaz collaborates closely with pharmaceutical sponsors, manufacturers, and clinical teams to overcome operational challenges and accelerate the successful delivery of clinical trials across the UK.

Seminars

Wednesday 2nd December 2026
Scaling Gallium-68 Production in the UK: Building Reliable Diagnostic Supply for the Next Generation of Radiopharmaceutical Development
11:00 am
  • Exploring the growing importance of Gallium-68 imaging in radiopharmaceutical clinical development and patient selection strategies
  • Navigating the operational, infrastructure and regulatory considerations required to establish and expand Gallium-68 production capabilities
  • Discussing how developers, manufacturers and clinical centres can work together to address supply constraints and support future radiopharmaceutical growth
Thursday 3rd December 2026
A Physician’s Perspective: Delivering RLTs at the Frontline of Patient Care & Witnessing Their Real-World Impact
8:30 am
  • Sharing personal experiences from treating patients with radioligand therapies, including the moments that transformed perceptions of what targeted radiation can achieve in oncology care
  • Reflecting on the emotional, clinical and human realities of guiding patients through RLT treatment journeys, from hope and uncertainty to long-term response and quality-of-life improvement
  • Exploring why physicians delivering these therapies believe radiopharmaceuticals have the potential to reshape cancer treatment paradigms and what still needs to change to bring these benefits to more patients earlier in their disease journey
Ajaaz Hussain